Abstract: An optimized protein-free tripartite vaccine that protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram-positive bacteria, Gram-negative bacteria, and fungi.

Abstract: A holster assembly includes a holster having an interior shaped to receive a handgun, and an entrance. An ejection port restraint pivotally connected to the holster includes a latch and is biased toward an obstruction position for engaging the latch with the ejection port of the handgun. A hood restraint pivotally connected to the holster body adjacent the entrance is configured to pivot between a non-obstruction position to permit the handgun to enter and to be drawn, and an obstruction position at which the hood restraint at least partially blocks the entrance. The hood restraint is biased toward the non-obstruction position. A release device mounted on the holster body is configured to actuate both the ejection port restraint and the hood restraint, each toward the respective non-obstruction position thereof, in response to a single movement by a user to allow the handgun to be withdrawn from the holster.

Abstract: To identify novel agents to treat carbapenem-resistant Acinetobacter baumannii. the Inventors used a nutrient-depleted medium with serum to mimic the in vivo environment. In RPMI with serum, the screen identified rifabutin (RBT) as being 133-fold more potent than rifampin (RIF) against A. baumannii, with MICs of 0.031 ?g/ml and 4 ?g/ml respectively. No difference in RBT vs. RIF activity was observed when MHII was used as the culture media. RBT possesses markedly superior in efficacy to RIF in murine models of lethal iv and pneumonia models of infection with a hyper-virulent, clinical lung and blood isolate of extreme-drug resistant (XDR) A. baumannii. In both models, RBT significantly improved survival and lowered bacterial burden compared to RIF. RBT is a promising, novel therapeutic option for A. baumannii infections.

Abstract: This disclosure provides a new vaccine composition and methods for its use. The composition contains an effective amount of each of: an aluminum hydroxide, a mono-phosphoryl lipid (MPL), and a whole glucan particles (WGP) but no an antigen that raises an immune response against a bacterial or fungal infection.

Abstract: An optimized protein-free tripartite vaccine that protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram-positive bacteria, Gram-negative bacteria, and fungi.

Abstract: A holster assembly includes a holster having an interior shaped to receive a handgun, and an entrance. An ejection port restraint pivotally connected to the holster includes a latch and is biased toward an obstruction position for engaging the latch with the ejection port of the handgun. A hood restraint pivotally connected to the holster body adjacent the entrance is configured to pivot between a non-obstruction position to permit the handgun to enter and to be drawn, and an obstruction position at which the hood restraint at least partially blocks the entrance. The hood restraint is biased toward the non-obstruction position. A release device mounted on the holster body is configured to actuate both the ejection port restraint and the hood restraint, each toward the respective non-obstruction position thereof, in response to a single movement by a user to allow the handgun to be withdrawn from the holster.

Abstract: To identify novel agents to treat carbapenem-resistant Acinetobacter baumannii. the Inventors used a nutrient-depleted medium with serum to mimic the in vivo environment. In RPMI with serum, the screen identified rifabutin (RBT) as being 133-fold more potent than rifampin (RIF) against A. baumannii, with MICs of 0.031 ?g/ml and 4 ?g/ml respectively. No difference in RBT vs. RIF activity was observed when MHII was used as the culture media. RBT possesses markedly superior in efficacy to RIF in murine models of lethal iv and pneumonia models of infection with a hyper-virulent, clinical lung and blood isolate of extreme-drug resistant (XDR) A. baumannii. In both models, RBT significantly improved survival and lowered bacterial burden compared to RIF. RBT is a promising, novel therapeutic option for A. baumannii infections.

Abstract: This disclosure provides a new vaccine composition and methods for its use. The composition contains an effective amount of each of: an aluminum hydroxide, a mono-phosphoryl lipid (MPL), and a whole glucan particles (WGP) but no an antigen that raises an immune response against a bacterial or fungal infection.

Abstract: A holster assembly includes a holster having an interior shaped to receive a handgun, and an entrance. An ejection port restraint pivotally connected to the holster includes a latch and is biased toward an obstruction position for engaging the latch with the ejection port of the handgun. A hood restraint pivotally connected to the holster body adjacent the entrance is configured to pivot between a non-obstruction position to permit the handgun to enter and to be drawn, and an obstruction position at which the hood restraint at least partially blocks the entrance. The hood restraint is biased toward the non-obstruction position. A release device mounted on the holster body is configured to actuate both the ejection port restraint and the hood restraint, each toward the respective non-obstruction position thereof, in response to a single movement by a user to allow the handgun to be withdrawn from the holster.

Abstract: A holster assembly includes a holster having an interior shaped to receive a handgun, and an entrance. An ejection port restraint pivotally connected to the holster includes a latch and is biased toward an obstruction position for engaging the latch with the ejection port of the handgun. A hood restraint pivotally connected to the holster body adjacent the entrance is configured to pivot between a non-obstruction position to permit the handgun to enter and to be drawn, and an obstruction position at which the hood restraint at least partially blocks the entrance. The hood restraint is biased toward the non-obstruction position. A release device mounted on the holster body is configured to actuate both the ejection port restraint and the hood restraint, each toward the respective non-obstruction position thereof, in response to a single movement by a user to allow the handgun to be withdrawn from the holster.

Abstract: This disclosure provides a new vaccine composition and methods for its use. The composition contains an effective amount of each of: an aluminum hydroxide, a mono-phosphoryl lipid (MPL), and a whole glucan particles (WGP) but no an antigen that raises an immune response against a bacterial or fungal infection.

Abstract: To identify novel agents to treat carbapenem-resistant Acinetobacter baumannii. the Inventors used a nutrient-depleted medium with serum to mimic the in vivo environment. In RPMI with serum, the screen identified rifabutin (RBT) as being 133-fold more potent than rifampin (RIF) against A. baumannii, with MICs of 0.031 ?g/ml and 4 ?g/ml respectively. No difference in RBT vs. RIF activity was observed when MHII was used as the culture media. RBT possesses markedly superior in efficacy to RIF in murine models of lethal iv and pneumonia models of infection with a hyper-virulent, clinical lung and blood isolate of extreme-drug resistant (XDR) A. baumannii. In both models, RBT significantly improved survival and lowered bacterial burden compared to RIF. RBT is a promising, novel therapeutic option for A. baumannii infections.